Vertex wins broader use of Kalydeco in CF
This article was originally published in Scrip
Vertex Pharmaceuticals on 21 February won approval from the FDA to expand the use of Kalydeco (ivacaftor) for use in eight additional mutations that cause cystic fibrosis, a rare, life-threatening genetic disease caused by a defective or missing CFTR protein, resulting from mutations in the CFTR gene, which causes poor flow of salt and water into and out of the cell in a number of organs, including the lungs.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.